Vaccine Table of Contents, June 20, 2003

Return to Vaccination News Home Page

Subscribe to the Vaccination NewsLetter

View past & current Scandals (columns by Sandy Mintz)

Search This Site using keywords

 

http://www.sciencedirect.com/science?_ob=IssueURL&_tockey=%23TOC%235188%232003%23999789978%23433502%23FLA%23Volume_21,_Issues_21-22,_Pages_2691-3094_(20_June_2003)&_auth=y&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=c81091569d4645d309880b59f17f9325

 

Vaccine
Copyright © 2003 Elsevier Ltd. All rights reserved

Volume 21, Issues 21-22, Pages 2691-3094 (20 June 2003)
   
           Selected Display Checked Docs  | E-mail Articles View:
1.
Letter to the Editor, Page 2691
Thavatchai Kamoltham, Henry Wilde and Thiravat Hemachudha
Abstract | Full Text + Links | PDF (31 K)
 
2.
Immunogenicity of recombinant HBsAg/HCV particles in mice pre-immunised with hepatitis B virus-specific vaccine, Pages 2692-2697
Hans J. Netter, Wai-Ping Woo, Robert Tindle, Roderick I. Macfarlan and Eric J. Gowans
Abstract | Full Text + Links | PDF (181 K)
 
3.
Evaluation of synthetic, M type-specific peptides as antigens in a multivalent group A streptococcal vaccine, Pages 2698-2703
M. Bruner, A. James, B. Beall, G. M. Carlone, E. Ades, S. Johnson, J. Guarner and J. Sampson
Abstract | Full Text + Links | PDF (76 K)
 
4.
Theoretic coverage of heptavalent pneumococcal conjugate vaccine in the prevention of community-acquired pneumonia in children in Italy, Pages 2704-2707
Susanna Esposito, Dace V. Madore, Stefania Gironi, Samantha Bosis, Silvia Tosi, Ciro Bianchi, Carolyn Cimino and Nicola Principi
Abstract | Full Text + Links | PDF (55 K)
 
5.
The predicted impact of private sector MMR vaccination on the burden of Congenital Rubella Syndrome, Pages 2708-2719
E. Vynnycky, N. J. Gay and F. T. Cutts
Abstract | Full Text + Links | PDF (231 K)
 
6.
Chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen, Der p 1 for oral vaccination in mice, Pages 2720-2729
Joon Lin Chew, Claudia Betina Wolfowicz, Hai-Quan Mao, Kam W. Leong and Kaw Yan Chua
Abstract | Full Text + Links | PDF (317 K)
 
7.
A recombinant fowl adenovirus expressing the S1 gene of infectious bronchitis virus protects against challenge with infectious bronchitis virus, Pages 2730-2736
Michael A. Johnson, Catherine Pooley, Jagoda Ignjatovic and Scott G. Tyack
Abstract | Full Text + Links | PDF (161 K)
 
8.
10 year assessment of infant hepatitis B vaccination program, in the Loyalty Islands (New Caledonia), Pages 2737-2742
Alain Berlioz-Arthaud, Philippe Perolat and Yves Buisson
Abstract | Full Text + Links | PDF (135 K)
 
9.
Non-responders to egg grown influenza vaccine seroconvert after booster immunization with MDCK cell grown vaccine, Pages 2743-2746
John S. Oxford, Ali A. Al-Jabri, Robert Lambkin, A. M. Palache and D. M. Fleming
Abstract | Full Text + Links | PDF (59 K)
 
10.
Intramuscular versus intradermal administration of anti-hepatitis B vaccine in non-cirrhotic hepatitis C patients, Pages 2747-2750
Eduardo Albéniz Arbizu, Rafael Bárcena Marugán, Javier Yuste Grijalba, Pilar López Serrano, Luis Gil Grande and Santos Del Campo Terrón
Abstract | Full Text + Links | PDF (64 K)
 
11.
Growth phase of orally administered Lactobacillus strains differentially affects IgG1/IgG2a ratio for soluble antigens: implications for vaccine development, Pages 2751-2757
Catharina B. M. Maassen, Wim J. A. Boersma, Conny van Holten-Neelen, Eric Claassen and Jon D. Laman
Abstract | Full Text + Links | PDF (112 K)
 
12.
Immunogenicity of a new Salmonella Typhi Vi polysaccharide vaccine––vax-TyVi®––in Cuban school children and teenagers, Pages 2758-2760
Rolando Felipe Ochoa Azze, Juan Carlos Martínez Rodríguez, Mónica Ginebra Iniesta, Xenia Rosa Ferriol Marchena, Vivian María Rodríguez Alfonso and Franklin Tomás Sotolongo Padrón
Abstract | Full Text + Links | PDF (55 K)
 
13.
A subunit vaccine against the adenovirus egg-drop syndrome using part of its fiber protein, Pages 2761-2766
E. Fingerut, B. Gutter, G. Gallili, A. Michael and J. Pitcovski
Abstract | Full Text + Links | PDF (137 K)
 
14.
A novel multivalent human CTL peptide construct elicits robust cellular immune responses in HLA-A*0201 transgenic mice: implications for HTLV-1 vaccine design, Pages 2767-2781
Roshni Sundaram, Yiping Sun, Christopher M. Walker, Francois A. Lemonnier, Steven Jacobson and Pravin T. P. Kaumaya
Abstract | Full Text + Links | PDF (268 K)
 
15.
BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa: A non-specific beneficial effect of BCG?, Pages 2782-2790
May-Lill Garly, Cesário Lourenco Martins, Carlitos Balé, Mamadu Aliu Baldé, Kathryn Louise Hedegaard, Per Gustafson, Ida M. Lisse, Hilton C. Whittle and Peter Aaby
Abstract | Full Text + Links | PDF (194 K)
 
16.
Correlation of body temperature with protection against staphylococcal enterotoxin B exposure and use in determining vaccine dose-schedule, Pages 2791-2796
James W. Boles, M. Louise M. Pitt, Ross D. LeClaire, Paul H. Gibbs, Robert G. Ulrich and Sina Bavari
Abstract | Full Text + Links | PDF (177 K)
 
17.
An improved Pythium insidiosum-vaccine formulation with enhanced immunotherapeutic properties in horses and dogs with pythiosis, Pages 2797-2804
Leonel Mendoza, William Mandy and Robert Glass
Abstract | Full Text + Links | PDF (409 K)
 
18.
Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus, Pages 2805-2812
Dan J. Smith, Simona Bot, Luis Dellamary and Adrian Bot
Abstract | Full Text + Links | PDF (176 K)
 
19.
DNA vaccination with the immunodominant tachyzoite surface antigen (SAG-1) protects against adult acquired Toxoplasma gondii infection but does not prevent maternofoetal transmission, Pages 2813-2820
Kevin N. Couper, Henrik V. Nielsen, Eskild Petersen, Fiona Roberts, Craig W. Roberts and James Alexander
Abstract | Full Text + Links | PDF (143 K)
 
20.
Immunogenicity of recombinant Mannheimia haemolytica serotype 1 outer membrane protein PlpE and augmentation of a commercial vaccine, Pages 2821-2829
Anthony W. Confer, Sahlu Ayalew, Roger J. Panciera, Marie Montelongo, Lisa C. Whitworth and Jordan D. Hammer
Abstract | Full Text + Links | PDF (304 K)
 
21.
Epidermal powder immunization of mice and monkeys with an influenza vaccine, Pages 2830-2836
Dexiang Chen, Ryan Endres, Yuh-Fun Maa, Charlotte R. Kensil, Patricia Whitaker-Dowling, Anita Trichel, Julius S. Youngner and Lendon G. Payne
Abstract | Full Text + Links | PDF (164 K)
 
22.
Enhanced adjuvanticity of interleukin-2 plasmid DNA administered in polyethylenimine complexes, Pages 2837-2843
Yu-Kyoung Oh, Jeong-Sook Park, Min-Jeong Kang, Jung Jae Ko, Jung Mogg Kim and Chong-Kook Kim
Abstract | Full Text + Links | PDF (276 K)
 
23.
A serine proteinase inhibitor (serpin) from ixodid tick Haemaphysalis longicornis; cloning and preliminary assessment of its suitability as a candidate for a tick vaccine, Pages 2844-2851
Maiko Sugino, Saiki Imamura, Albert Mulenga, Mie Nakajima, Akiko Tsuda, Kazuhiko Ohashi and Misao Onuma
Abstract | Full Text + Links | PDF (279 K)
 
24.
Induction of protective immunity by DNA vaccination with Toxoplasma gondii HSP70, HSP30 and SAG1 genes, Pages 2852-2861
Rabie M. Mohamed, Fumie Aosai, Mei Chen, Hye-Seong Mun, Kazumi Norose, Usama S. Belal, Lian-Xun Piao and Akihiko Yano
Abstract | Full Text + Links | PDF (335 K)
 
25.
Optimising vaccination strategies in equine influenza, Pages 2862-2870
A. W. Park, J. L. N. Wood, J. R. Newton, J. Daly, J. A. Mumford and B. T. Grenfell
Abstract | Full Text + Links | PDF (489 K)
 
26.
Comparison of PorA VR types and porA promoter sequence from Neisseria meningitidis B isolated from non-immunised children and vaccine failures immunised with a serogroup B outer membrane protein vaccine, Pages 2871-2876
Maria Cecília O. Gorla, Ana Paula S. Lemos, Claudio T. Sacchi, José Cássio de Moraes and Lucimar G. Milagres
Abstract | Full Text + Links | PDF (105 K)
 
27.
Reflections on the meningococcal group C infection immunisation campaign: views from the sharp end, Pages 2877-2881
M. Lansley and H. Bedford
Abstract | Full Text + Links | PDF (56 K)
 
28.
Enhancement of Sm-p80 (large subunit of calpain) induced protective immunity against Schistosoma mansoni through co-delivery of interleukin-2 and interleukin-12 in a DNA vaccine formulation, Pages 2882-2889
Afzal A. Siddiqui, Troy Phillips, Hugues Charest, Ron B. Podesta, Martha L. Quinlin, Justin R. Pinkston, Jenny D. Lloyd, Janet Pompa, Rachael M. Villalovos and Michelle Paz
Abstract | Full Text + Links | PDF (278 K)
 
29.
Optimization of epicutaneous immunization for the induction of CTL, Pages 2890-2899
Roopjeet Kahlon, Yuxiang Hu, Catherine H. Orteu, Arnawaz Kifayet, Jacqueline D. Trudeau, Rusung Tan and Jan P. Dutz
Abstract | Full Text + Links | PDF (259 K)
 
30.
Gene gun immunization in a preclinical model is enhanced by B7 targeting, Pages 2900-2905
Mary Tachedjian, Jeff S. Boyle, Andrew M. Lew, Biserka Horvatic, Jean-Pierre Y. Scheerlinck, Jan M. Tennent and Marion E. Andrew
Abstract | Full Text + Links | PDF (144 K)
 
31.
The immunogenicity of oral poliomyelitis vaccine in a primary vaccination series at 2, 4 and 6 months given concurrently with Hib, hepatitis B and diphtheria, tetanus and whole-cell pertussis vaccines administered as three separate injections or as a combination pentavalent vaccine, Pages 2906-2910
Katharine Hogg and Geoff Hogg
Abstract | Full Text + Links | PDF (62 K)
 
32.
Porcine Ig isotypes: function and molecular characteristics, Pages 2911-2922
A. Crawley and B. N. Wilkie
Abstract | Full Text + Links | PDF (439 K)
 
33.
CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP119) formulated in oil-based Montanides, Pages 2923-2932
C. Hirunpetcharat, J. Wipasa, S. Sakkhachornphop, T. Nitkumhan, Y. Z. Zheng, S. Pichyangkul, A. M. Krieg, D. S. Walsh, D. G. Heppner and M. F. Good
Abstract | Full Text + Links | PDF (283 K)
 
34.
Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials, Pages 2933-2947
P. B. Gilbert, Y. -L. Chiu, M. Allen, D. N. Lawrence, C. Chapdu, H. Israel, D. Holman, M. C. Keefer, M. Wolff, S. E. Frey and NIAID HIV Vaccine Trials Network
Abstract | Full Text + Links | PDF (128 K)
 
35.
Immunity against measles in populations of women and infants in Poland, Pages 2948-2953
Wieslawa Janaszek and Janusz Slusarczyk
Abstract | Full Text + Links | PDF (234 K)
 
36.
Frequent nasal administrations of recombinant cholera toxin B subunit (rCTB)-containing tetanus and diphtheria toxoid vaccines induced antigen-specific serum and mucosal immune responses in the presence of anti-rCTB antibodies, Pages 2954-2963
Yoko Yasuda, Masanori Isaka, Tooru Taniguchi, Yanqiu Zhao, Keiko Matano, Hideyuki Matsui, Kazunori Morokuma, Jun-ichi Maeyama, Kunio Ohkuma, Norihisa Goto and Kunio Tochikubo
Abstract | Full Text + Links | PDF (430 K)
 
37.
CD40 ligand (CD154) improves the durability of respiratory syncytial virus DNA vaccination in BALB/c mice, Pages 2964-2979
Jennifer L. Harcourt, Michael P. Brown, Larry J. Anderson and Ralph A. Tripp
Abstract | Full Text + Links | PDF (682 K)
 
38.
Response of calves persistently infected with noncytopathic bovine viral diarrhea virus (BVDV) subtype 1b after vaccination with heterologous BVDV strains in modified live virus vaccines and Mannheimia haemolytica bacterin-toxoid, Pages 2980-2985
Robert W. Fulton, Douglas L. Step, Julia F. Ridpath, Jeremiah T. Saliki, Anthony W. Confer, Bill J. Johnson, Robert E. Briggs, R. V. Hawley, Lurinda J. Burge and Mark E. Payton
Abstract | Full Text + Links | PDF (75 K)
 
39.
Standardisation and establishment of a rabies ELISA test in European laboratories for assessing the efficacy of oral fox vaccination campaigns, Pages 2986-2993
Florence Cliquet, Thomas Müller, Franco Mutinelli, Sabrina Geronutti, Bernard Brochier, Thomas Selhorst, Jean-Luc Schereffer, Nicolas Krafft, Jeanette Burow, Astrid Schameitat et al.
Abstract | Full Text + Links | PDF (235 K)
 
40.
Pathogenicity and neurovirulence of a mutagen-attenuated Rift Valley fever vaccine in rhesus monkeys, Pages 2994-3002
J. C. Morrill and C. J. Peters
Abstract | Full Text + Links | PDF (131 K)
 
41.
Construction and characterization of rhesus monkey rotavirus (MMU18006)- or bovine rotavirus (UK)-based serotype G5, G8, G9 or G10 single VP7 gene substitution reassortant candidate vaccines, Pages 3003-3010
Yasutaka Hoshino, Ronald W. Jones, Jerri Ross and Albert Z. Kapikian
Abstract | Full Text + Links | PDF (192 K)
 
42.
Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants, Pages 3011-3018
Scott Jendrek, Stephen F. Little, Stanley Hem, Gautam Mitra and Steven Giardina
Abstract | Full Text + Links | PDF (257 K)
 
43.
Regional, but not systemic recruitment/expansion of dendritic cells by a pluronic-formulated Flt3-ligand plasmid with vaccine adjuvant activity, Pages 3019-3029
Hongxun Sang, Vladimir M. Pisarev, Corey Munger, Simon Robinson, Jennifer Chavez, Lori Hatcher, Prahlad Parajuli, Yajun Guo and James E. Talmadge
Abstract | Full Text + Links | PDF (473 K)
 
44.
The protective efficacy of MSP4/5 against lethal Plasmodium chabaudi adami challenge is dependent on the type of DNA vaccine vector and vaccination protocol, Pages 3030-3042
A. Rainczuk, P. M. Smooker, L. Kedzierski, C. G. Black, R. L. Coppel and T. W. Spithill
Abstract | Full Text + Links | PDF (468 K)
 
45.
Protective efficacy of oral immunization with heat-killed Shigella flexneri 2a in animal model: study of cross protection, immune response and antigenic recognition, Pages 3043-3050
A. Mukhopadhaya, D. Mahalanabis, J. Khanam and M. K. Chakrabarti
Abstract | Full Text + Links | PDF (129 K)
 
46.
Oral immunisation with live aroA attenuated Salmonella enterica serovar Typhimurium expressing the Yersinia pestis V antigen protects mice against plague, Pages 3051-3057
Helen S. Garmory, Kate F. Griffin, Katherine A. Brown and Richard W. Titball
Abstract | Full Text + Links | PDF (158 K)
 
47.
Immunization with recombinant paraflagellar rod protein induces protective immunity against Trypanosoma cruzi infection, Pages 3058-3069
Keith A. Luhrs, David L. Fouts and Jerry E. Manning
Abstract | Full Text + Links | PDF (245 K)
 
48.
Genetic immunization with LYT1 or a pool of trans-sialidase genes protects mice from lethal Trypanosoma cruzi infection, Pages 3070-3080
Bolyn H. Fralish and Rick L. Tarleton
Abstract | Full Text + Links | PDF (228 K)
 
49.
Mucosal co-administration of cholera toxin and influenza virus hemagglutinin-DNA in ponies generates a local IgA response, Pages 3081-3092
G. Soboll, K. M. Nelson, E. S. Leuthner, R. J. Clark, R. Drape, M. D. Macklin, W. F. Swain, C. W. Olsen and D. P. Lunn
Abstract | Full Text + Links | PDF (365 K)
 
50.
Corrigendum to "Immunogenic measles antigens expressed in plants: role as an edible vaccine for adults" [Vaccine 21 (2003) 816–819], Page 3093
Claude P. Muller, Estelle Marquet-Blouin, Fred Fack, Benjamin Damien, André Steinmetz and Fabienne B. Bouche
Abstract | Full Text + Links | PDF (29 K)
 
51.
Call for papers: viral vaccine meeting, Page 3094

PDF (26 K)
 
52.
Call for papers:8-11 November 2003,The Evergreen Conference Resort, Stone Mountain, Georgia, USA, Page I

PDF (27 K)
 
53.
Editorial Board/Aims and Scope, Page CO2

PDF (43 K)
 


 

Issues
HomeBrowse JournalsBrowse Abstract DatabasesBrowse Reference WorksMy AlertsMy Profile   Help (Opens new window)


 

Send feedback to ScienceDirect
Software and compilation © 2003 ScienceDirect. All rights reserved.
ScienceDirect® is an Elsevier Science B.V. registered trademark.


Your use of this service is governed by Terms and Conditions. Please review our Privacy Policy for details on how we protect information that you supply.

 

 

Return to Vaccination News Home Page

DISCLAIMER:    All information, data, and material contained, presented, or provided here is for general information purposes only and is not to be construed as reflecting the knowledge or opinions of the publisher, and is not to be construed or intended as providing medical or legal advice.  The decision whether or not to vaccinate is an important and complex issue and should be made by you, and you alone, in consultation with your health care provider.